From: clinicaltrialsarena.com Eli Lilly has reported positive patient-reported outcomes (PRO) from a late-stage trial testing the efficacy of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC). Eli Lilly has reported positive patient-reported outcomes (PRO) from a late-stage trial testing the efficacy of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC). The move comes after a primary outcome analysis …
-
-
Breast Cancer Survivors Making a Difference in Breast Cancer Awareness Month
-
Pain for a Breast Cancer Survivor
-
A World Turned Upside Down After a Breast Cancer Diagnosis
-
This Breast Cancer Survivor Won’t Settle for Being Mediocre
-
Please Don’t Tell a Breast Cancer Survivor What To Do
